Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Antibodies to intracellular antigens
- Antibodies to membrane-bound antigens
- High sensitivity of autoantibodies to membrane-bound antigens
- Low sensitivity of autoantibodies to intracellular antigens
- Targets of autoantibodies
- SS-A/Ro-like fine speckled nuclear ANA pattern
- The case for anti-SS-A/Ro 60kDa antibodies
- In vivo antinuclear antibody phenomenon in mice
- In vivo antinuclear antibody phenomenon in humans
- Antibody-dependent cell cytotoxicity in cultures keratinocytes
- ANCA (anti-neutrophil cytoplasm antibodies)
- Clinical evidence for pathogenic role of ANCA
- Experimental evidence for pathogenic role of ANCA
- The case of antibodies to chromatin
- Plasmacytoid dendritic cells internalize immune complexes
- Immune-mediated necrotizing myopathies (IMNM)
- Clinical characteristics of IMNM
- 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase
- Signal Recognition Particle (SRP)
- Pathogenicity of anti-SRP and anti-HMGCR antibodies
- In vivo pathogenicity of anti-SRP or anti-HMGCR autoantibodies
- Anti-SRP antibodies decrease grip and muscle strength
- Anti-HMGCR antibodies decrease grip and muscle strength
- Anti-SRP or anti-HMGCR antibodies induce necrosis of myofibers
- Immunization with recombinant SRP or HMGCR
- C3 KO abrogates anti-SRP or anti-HMGCR mediated disease
- Pathogenicity of autoantibodies
- Autoantibodies to antigens at the outer cell surface
- Transient disease after placental transfer of autoantibodies
- Autoantibodies against antigens of the epithelial intercellular cement
- Anti-desmoglein 3 antibodies & Pemphigus vulgaris
- Molecular mechanisms of anti-desmoglein 3 antibodies pathogenicity
- Immune-mediated membranous nephropathy (1)
- Immune-mediated membranous nephropathy (2)
- Pathogenicity of antibodies to NEP
- Neonatal membranous GN
- Autoantibodies to PLA2R
- Serum anti-PLA2R and proteinuria under treatment
- Anti-PLA2R serum levels & disease activity & prognosis
- Chronic idiopathic urticaria
- Autoantibodies in chronic idiopathic urticaria
- Evidence for pathogenicity of anti-FcεRIα antibodies
- In vivo autologous serum skin test
- In vitro activation of basophils from autologous serum
- Autoimmune encephalopathies (1)
- Autoimmune encephalopathies (2)
- Characteristic topographic distribution for each targeted autoantigen
- Neurologic diseases & autoantibodies to surface antigens
- NMDA receptor
- NMDA receptor encephalopathy
- Pathogenic autoantibodies targeting NMDA receptors
- Transient anti-NMDAR encephalitis due to transplacental transmission
- Eugène Devic’s (1894)
- Devic’s neuromyelitis optica
- Anti-aquaporin 4 antibodies
- Pathogenic role of anti-aquaporin 4 antibodies: pros & cons
- Pathogenicity of anti-aquaporin 4 depends on complement
- Concluding remarks
Topics Covered
- Autoantibodies targeting cell membrane-bound antigens
- Autoantibodies targeting intracellular antigens
- Autoantibodies as a result of damage to target tissues
- Autoantibodies preceding the clinical onset of diseases
- Pathogenic autoantibodies in rheumatology, neurology, dermatology and nephrology
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Andrade, L.E.C. (2020, June 30). Pathogenic mechanisms of autoantibodies: antibodies to intracellular and membrane-bound antigens [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/JQHI9795.Export Citation (RIS)
Publication History
Financial Disclosures
- There are no commercial/financial matters to disclose.
Pathogenic mechanisms of autoantibodies: antibodies to intracellular and membrane-bound antigens
Published on June 30, 2020
34 min
A selection of talks on Immunology & Inflammation
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Luis Andrade.
I am an Associate Professor of Medicine at Universidade Federal De São Paulo, Brazil,
Medical Consultant for Immunology at the Fleury Laboratory and
Chair of the Quality Standardization and Assessment Committee of the IUIS.
In the second part of the talk on pathogenic mechanisms of autoantibodies,
I will focus on antibodies to intracellular antigens and to
membrane-bound antigens and discuss
possible pathogenic mechanisms for these two classes of autoantibodies.
0:43
At this point, it is important to consider that we have two classes of autoantigens;
intracellular and extracellular antigens.
Antibodies to intracellular antigens include chromatin antigen, spliceosome antigens,
DNA topoisomerase 1, tRNA synthetases,
liver kidney microsome, mitochondria pyruvate, SS-B/La.
1:14
Examples of antigens to
extracellular membrane-bound antigens include acetylcholine receptor, aquaporin 4,
phospholipase A2, desmoglein I and III, thyrotropin receptor antibody,
glycoproteins IIb-IIIa or Ib-IX from platelets,
and the proton pump and intrinsic factor in gastric mucosa.
Hide